Dr Ola Landgren from Memorial Sloan Kettering, New York, USA, tells the European Medical Journal about the possible enormous value of minimal residual disease (MRD) monitoring in multiple myeloma (MM) as a potential new end-point in MM clinical trials, and as a marker of therapeutic response.
Author: admin
Dr Ola Landgren from Memorial Sloan Kettering, New York, USA, summarises recent plethora of data in patients with newly diagnosed myeloma. A key recent advance is to treat patients more aggressively earlier with three drug combinations. He outlines latest views on MRD (minimal residual disease), and highlights the promising findings in older patients .
Dr Ola Landgren from Memorial Sloan Kettering, New York, USA, summarises recent plethora of data in patients with newly diagnosed myeloma. A key recent advance is to treat patients more aggressively earlier with three drug combinations. He outlines latest views on MRD (minimal residual disease), and highlights the promising findings in older patients .
Dr Ola Landgren from Memorial Sloan Kettering, New York, USA, speaks to the European Medical Journal from the 19th Congress of the European Haematology Association (EHA) meeting about the changed definition of multiple myeloma. A result of a 2-day workshop of the international myeloma working group before the EHA meeting, the definition now includes three additional criteria which are explained. Dr Landgren explores the reason for the altered definition and implications for clinical practice.
Speaking to the European Medical Journal from the 19th Congress of the European Haematology Association (EHA) meeting, Prof. John Seymour from Sir Peter MacCallum, Department of Oncology, Australia, outlines the three presentations at the meeting updating clinicians on the latest findings with ABT199 , an investigational B-cell lymphoma 2 (BCL-2) selective inhibitor. Firstly, he outlines the results from the monotherapy dose-escalation study, which has completed recruitment (n=105) and shown positive clinical findings. Secondly , he summarises the findings from the step-wise programme developed to avoid tumour lysis syndrome with ABT199. Thirdly , Prof. Seymour discusses the promising early data from…
Dr Kenneth Anderson, Multiple Myeloma Boston 2014 congress round-up
Prof. Peter Hillmen from Leeds Teaching Hospital, Leeds, UK, gives an update on the phase III results from the RESONATE study in 391 patients with relapsed refractory chronic lymphoid leukemia (CLL). Prof Hillmen outlines the PFS and OS results that showed the significant benefits of ibrutinib over ofatumumab. He comments on single vs. combination therapy with ibrutinib in CLL.
Speaking to EMJ from the 19th Congress of the European Hematology Association (EHA 19) meeting, Prof. Paul Richardson , Dana-Farber Cancer Institute, USA, discusses results seen from the breakthrough PANORAMA1 study, a global randomised, double-blind, placebo-controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma. He outlines the primary end-point results and side effects observed, and comments on the clinical meaningfulness of these HDAC trial results. Results of sub-sets of higher risk groups are also discussed, and Prof Richardson comments on new data with ricolinostat (ACY-1215) in multiple myeloma. Keywords: EMJ Relapsed…
Prof. Simon Rule from Plymouth Hospital, UK, discusses data presented at EHA19 on the second-generation oral BTK inhibitor, ONO-4059. One study presented relates to CLL; the other to non-Hodgkins lymphoma (NHL). In both studies, ONO-4059 shows promising results that might allow it to compete with ibrutinib. He also outlines the benefits seen with ibrutinib in several haematological cancers, and a poster showing two-year ibrutinib toxicity data.
Prof. Valeria Santini, University of Florence Medical School, Italy, highlights novel mutational and genetic studies in MDS presented atEHA19 which might in the future translate into clinical benefits. One involves a significantly sensitive and sophisticated prognostic scoring system; another involves gene expression in MDS that may allow the classification of patients according to prognosis. Keywords: Myelodysplastic Syndrome (MDS) Prof. Valeria Santini University of Florence Medical School Genetic studies in MDS EHA19
Prof. Stephan Stilgenbauer from University of Ulm, Germany, defines ultra high-risk CLL (chronic lymphocytic leukemia) and comments on its implications for patients. He outlines highlights from ASCO 2014 and EHA 2014 in CLL, addressing the latest data with ibrutinib from the RESONATE trial, and on resistance issues observed with ibrutinib. He also comments on the use of single vs. combination agents in CLL – including new treatments such as ibrutinib, idelalisib, and ABT199. Keywords: EMJ Ultra high-risk CLL Ibrutinib Prof. Stephan Stilgenbauer University of Ulm Chronic Lymphocytic Leukemia (CLL) ASCO 2014 EHA 2014 RESONATE trial Ibrutinib Idelalisib ABT199
Held annually in South Florida every January, The Symposium on Clinical Interventional Oncology (CIO) features a concentrated 2-day program renowned for its originality, patient-care focus and dynamic learning format. CIO focuses on highlighting the most viable and sought-after treatments in interventional oncology while shining a spotlight on current best practices and previewing developments on the horizon. CIO is the must-attend symposiumof the year for IO novices and expert learners searching to stay on the brink of innovation of contemporary techniques, methodologies and technological advances. Join your peers and attend North Americas fastest growing meeting in the IO arena. We look…
When it comes to EGFR and lung cancer, is a mutation good or bad? Dr. Joel Neal of Stanford University Medical Center explains why non-mutated genes are called “wild type.” February 2014.
Prof David Cameron from The Edinburgh Cancer Research Centre is committed to identifying potential new approaches to treating and preventing breast cancer. We caught up with him at EBCC9 in Glasgow to find out what’s new for breast cancer patients. He tells us about ongoing research as well as some of the findings that were being presented at the congress.
A retrospective study of the effect of extending mammography to age 75 was performed in the Netherlands to use data emerging from the change of policy shifting age-based mammography to 75 in 1999. More early stage tumours were detected but just as many cases of late-stage disease were discovered as before, implying that screening had not eliminated them and was not yielding a benefit. Further analysis confirmed that the harmful effects of over-treatment in this age group were outweighing any potential benefits of cancer detection. Dr. Liefers concluded that age-based screening is failing these patients who should receive mammography on…
A detailed analysis of risk factors including genomic markers of women with breast cancer has revealed that three-year mammographic screening is insufficient for around half of all women who could be candidates for annual screening. This is good news for regions where annual screening is the norm as it suggests a potential saving by screening less frequently in one subgroup, but perhaps less welcome news in countries such as the UK where three-year screening is recommended.
A massive Oxford meta-analysis they have completed has shown that adjuvant radiotherapy gives absolute benefits in terms of progression-free and overall- survival in women with breast cancer who have one, two, or three involved axillary lymph nodes clarifying a long-held uncertainty. Up to now four or more nodes has been a status known to benefit from R/T, while node-zero did not confer any benefit from R/T. The effect is surprisingly large and is just as strong among women who received either chemotherapy or endocrine therapy extending considerably the application of adjuvant radiotherapy.
Dr Poortmans presented a late breaking abstract at a workshop on the regional control of breast cancer, along with speakers from Denmark, Canada and the UK. His abstract was on the updated results of his groups EORTC ROG and BCG phase III trial22922/10925 confirming the benefits of chest irradiation for patients with early breast cancer irrespective of their axillary nodal status. One of the key new points the data were presently able to confirm was that such regional radiotherapy extends life not only in chemotherapy-naïve patients, but also in those who have received extensive systemic therapy.
Dr. Mark Socinski is a Professor of Medicine, University of Pittsburgh School of Medicine. In this video, he answers common questions about the role of the PD-1 checkpoint pathway in normal immune function and tumor immune evasion.
7° Riunione Nazionale A.I.G. Associazione Italiana GIST Onlus Bologna, 29 marzo 2014
Gestione degli effetti collaterali delle terapie e delle complicanze post-chirurgiche 7 ° Riunione Nazionale AIG Associazione Italiana GIST Onlus Bologna, 29-03-2014
Stato dell’arte e ricerca clinica attuale (SECONDA PARTE) 7 ° Riunione Nazionale AIG Associazione Italiana GIST Onlus Bologna 29 marzo 2014
Il percorso della ricerca nei GIST in laboratorio. 7° Riunione Nazionale A.I.G. Associazione Italiana GIST Onlus Bologna, 29 marzo 2014
7° Riunione Nazionale A.I.G. Associazione Italiana GIST Onlus Bologna, 29 marzo 2014
Caso clinico 3: terapia con Regorafenib in terza linea di trattamento. 7° Riunione Nazionale A.I.G. Associazione Italiana GIST Onlus Bologna, 29 marzo 2014
7° Riunione Nazionale A.I.G. Associazione Italiana GIST Onlus Bologna, 29 marzo 2014
Don Sharpe talks to Terri Guidi, MBA of Oncology Management and Consulting about a real life case study of an analysis of oncology practice value to the hospital.
Don Sharpe sits down with Ted Okon the Executive Director of The Community Oncology Alliance and they talk about what’s impacting cancer care at the COA annual meeting.
Don Sharpe talks to Ricky Newton, CPA of Cancer Specialists of Tidewater about how to understand the business issue of quality cancer care. The interview was presented at COA annual meeting.
Don Sharpe talks to Dr. Jeff Vacirca, MD of North Shore Hematology and Oncology concerning the Effects of Sequestration to Community Oncologists.
Don Sharpe of OBR interviews Dr. Ira Klein, MD where he asks What is Gene Forward and Gene Backward?
Don Sharpe sits down with Dr. Brian Van Tine, MD PhD or Washington University to talk about Management and Treatment of Sarcoma.
Don Sharpe discusses the Payer Perspective on Molecular Testing with Dr. Micheal Kolodziej, MD from Aetna at the COA annual meeting.
Don Sharpe of OBR talks about the variances in genetic testing and how that may affect health care decisions with Dr. Lee Newcomer, MD of UnitedHealthCare.
Don Sharpe talks about Molecular Testing for Cancer from a Payer Perspective with Dr. Sundeep Reddy, MD (Caris Life Sciences) at the COA annual meeting.
Don Sharpe of OBR discusses the topic What’s Making Your Oncologist Sick? with Dr. Joseph Lynch, MD at the COA annual meeting.
Don Sharpe talks to Rebecca Bechhold, MD about Integrating Palliative Care and Oncology from the COA annual meeting in Orlando.
Don Sharpe of OBR discusses The Genetic Science Behind Heredity Colon Cancer Syndromes with Dr. Larry Geier, MD at the COA annual meeting.
Don Sharpe of OBR discusses The Medical Home past and future with Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance.
Don Sharpe of OBR discusses how an oncology practice get’s started with The Medical Home model and the implemenation process with Carol Murtaugh, RN, OCN of Hematology & Oncology Consultants. Interview conducted at the annual COA meeting in Orlando, FL.
Don Sharpe of OBR discusses the progress for payers who are using The Medical Home model with Gordon Kuntz of ION Solutions at the annual COA meeting in Orlando, FL.
Don Sharpe of OBR talks to Dr. Daniel McKeller, MD of the Commission on Cancer about the report on The Medical Home. The interview was at COA annual meeting.
Don Sharpe talks to Stuart Genschaw, Exec. Dir. of Cancer & Hematology Centers of Western Michigan about innovation within oncology payment reforms from the COA annual meeting.
Don Sharpe asks the question Why are you embracing payment reform at The Center for Cancer and Blood Disorders to Barry Russon, CEO. Community Oncology Alliance annual meeting.
Don Sharpe discusses the success at Advanced Medical Specialties using Accountable Care Organization (ACO) with Dr. Leonard Kalman, MD from the annual COA meeting.
Don Sharpe talks to Dr. Barbara McAneny, MD from New Mexico Cancer Center about the CMMI Award and setting up The Medical Home at the COA meeting in Orlando.
Don Sharpe talks about the importance of cancer patient advocacy from the point of view of a medical oncologists Dr. Erin Dunbar, MD of Piedmont Healthcare.
Don Sharpe discusses Dr Erin Dunbar, MD or Piedmont Healthcare her presentation entitled “Good News from the Oncologist” at the COA annual meeting.
Don Sharpe of OBR talks to Dr. Lucio Gordon, MD of Florida Cancer Specialists about the role of IT, Electronic Medical Records, and Big Data in the future for oncology.
Don Sharpe talks to Angel Aslo, PharmD about the role of in house pharmacies within the community oncology setting.